News

Public · Published

Theriva™ Biologics Announces Sale Of Syn-004 (Ribaxamase) And Related Antibiotic-Degrading Enzyme Portfolio To Biossil Labs Inc.

Theriva Biologics announced the sale of Syn-004, also called ribaxamase, and its related antibiotic-degrading enzyme portfolio to Biossil Labs Inc. The supplied article provides no sale price, closing date, or other transaction terms.

Published:

Updated:

What happened

Theriva Biologics announced the sale of Syn-004, also called ribaxamase, and its related antibiotic-degrading enzyme portfolio to Biossil Labs Inc. The supplied article provides no sale price, closing date, or other transaction terms.

Confirmed

Global impact / market context

The sale transfers control of Syn-004 and the related portfolio to Biossil Labs. Depending on the terms, proceeds could add cash for Theriva, while giving up future rights could limit its ability to earn revenue if these assets are developed or commercialized.

Analyst inference

The announcement identifies a buyer and the assets being sold, but gives no price or terms to indicate the deal’s financial scale. Investors therefore cannot assess from this report alone whether cash proceeds, lost future revenue, or both could be significant for Theriva.

Analyst inference

What to watch

  1. Look for disclosed sale proceeds and payment terms; these would show how much cash Theriva receives and whether payment is immediate or depends on later conditions. Analyst inference
  2. Watch for details about which development, manufacturing, or commercial rights transfer to Biossil, since those rights determine who can pursue revenue from the portfolio. Analyst inference
  3. Any announcement of completion, required approvals, or conditions would clarify when control changes hands and whether the announced sale proceeds as planned. Analyst inference

Evidence

  • Original source link unavailable